tetano
Editor, Senior Moderator
J Neurovirol
. 2022 Apr 2.
doi: 10.1007/s13365-022-01066-3. Online ahead of print.
Post-COVID-19 olfactory dysfunction: carbamazepine as a treatment option in a series of cases
Claudia Cristina Ferreira Vasconcelos[SUP] #[/SUP][SUP] 1 [/SUP], Mariana Beiral Hammerle[SUP] #[/SUP][SUP] 2 [/SUP], Deborah Santos Sales[SUP] 1 [/SUP], Fernanda Cristina Rueda Lopes[SUP] 3 4 [/SUP], Patricia Gomes Pinheiro[SUP] 1 [/SUP], Elisa Gutman Gouvea[SUP] 1 [/SUP], Manuella Caroline Dutra Frazão Alves[SUP] 1 [/SUP], Tayane Vasconcellos Pereira[SUP] 1 [/SUP], Sergio Luis Schmidt[SUP] 1 [/SUP], Regina Maria Papais Alvarenga[SUP] 1 [/SUP], Karina Lebeis Pires[SUP] 1 [/SUP]
Affiliations
Abstract
Olfactory dysfunction is reported frequently in patients with coronavirus disease 2019. However, an effective treatment for this dysfunction is unknown. The present study evaluated carbamazepine as a treatment option for olfactory dysfunction based on its use in cases of neuralgia, especially of the V cranial nerve. The study included 10 patients with coronavirus disease with olfactory complaints who were part of a cohort of 172 coronavirus disease patients monitored for late neurological manifestations. Carbamazepine was administered for 11 weeks. The adverse effects reported were drowsiness (9/10) and dizziness (2/10); 9 of the 10 patients reported improved olfactory function after carbamazepine treatment. While the role of carbamazepine in the control of post-coronavirus disease olfactory dysfunction could not be confirmed in this study, the satisfactory response observed in most patients in this series suggests that further studies are warranted.
Keywords: Anosmia; COVID-19; Carbamazepine; SARS-CoV-2.
. 2022 Apr 2.
doi: 10.1007/s13365-022-01066-3. Online ahead of print.
Post-COVID-19 olfactory dysfunction: carbamazepine as a treatment option in a series of cases
Claudia Cristina Ferreira Vasconcelos[SUP] #[/SUP][SUP] 1 [/SUP], Mariana Beiral Hammerle[SUP] #[/SUP][SUP] 2 [/SUP], Deborah Santos Sales[SUP] 1 [/SUP], Fernanda Cristina Rueda Lopes[SUP] 3 4 [/SUP], Patricia Gomes Pinheiro[SUP] 1 [/SUP], Elisa Gutman Gouvea[SUP] 1 [/SUP], Manuella Caroline Dutra Frazão Alves[SUP] 1 [/SUP], Tayane Vasconcellos Pereira[SUP] 1 [/SUP], Sergio Luis Schmidt[SUP] 1 [/SUP], Regina Maria Papais Alvarenga[SUP] 1 [/SUP], Karina Lebeis Pires[SUP] 1 [/SUP]
Affiliations
- PMID: 35366736
- DOI: 10.1007/s13365-022-01066-3
Abstract
Olfactory dysfunction is reported frequently in patients with coronavirus disease 2019. However, an effective treatment for this dysfunction is unknown. The present study evaluated carbamazepine as a treatment option for olfactory dysfunction based on its use in cases of neuralgia, especially of the V cranial nerve. The study included 10 patients with coronavirus disease with olfactory complaints who were part of a cohort of 172 coronavirus disease patients monitored for late neurological manifestations. Carbamazepine was administered for 11 weeks. The adverse effects reported were drowsiness (9/10) and dizziness (2/10); 9 of the 10 patients reported improved olfactory function after carbamazepine treatment. While the role of carbamazepine in the control of post-coronavirus disease olfactory dysfunction could not be confirmed in this study, the satisfactory response observed in most patients in this series suggests that further studies are warranted.
Keywords: Anosmia; COVID-19; Carbamazepine; SARS-CoV-2.